CinDome Pharma

Year Invested/Status: 2016/Active
Motivation: 1 in 4 adult patients in the US experience symptoms of gastroparesis – pain, bloating, nausea and vomiting – with the incidence growing rapidly due to the increasing diabetic population [1,2]. A safe and effective treatment that can be taken on a chronic basis remains a significant unmet need.

Lead Program(s): CIN-102 (deudomperidone) is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being developed to treat patients with gastrointestinal disorders currently in phase 2 of clinical development. CIN-102 has secured composition of matter patents as well as completed a proof-of-concept study showing signals of improvement in nausea and vomiting and promising effect on gastric emptying in patients with gastroparesis.

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-102
Gastroparesis

Sources:
[1] Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Digestive Diseases and Sciences. 1993;38(9):1569–1580.
[2] Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clinical Gastroenterology and Hepatology. 2005;3(6):543–552.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES